Abstract：
OBJECTIVE: There is limited safety data on the use of everolimus during pregnancy. In this study, we present the maternal and neonatal outcomes of everolimus used throughout the course of pregnancy and conducted a systematic review of reports of everolimus use after organ transplantation during pregnancy.
METHODS: A woman with type 1 diabetes who underwent kidney transplantation was treated with tacrolimus, everolimus, and prednisolone. Two years later, she became pregnant. At 27 weeks of gestation, an emergent cesarean delivery was performed owing to severe preeclampsia and fetal distress. No congenital malformation was noted in the baby at a corrected age of 4 months, and the maternal renal function remained stable.
CONCLUSIONS: Our systematic review did not identify evidence of teratogenicity in babies exposed to everolimus as an immunosuppressant after transplantation. To better assess the risk of exposure to everolimus during pregnancy, all cases of new pregnancies occurring in transplant recipients receiving treatment with mammalian target of rapamycin inhibitor inhibitors should be reported.
METHODS: A woman with type 1 diabetes who underwent kidney transplantation was treated with tacrolimus, everolimus, and prednisolone. Two years later, she became pregnant. At 27 weeks of gestation, an emergent cesarean delivery was performed owing to severe preeclampsia and fetal distress. No congenital malformation was noted in the baby at a corrected age of 4 months, and the maternal renal function remained stable.
CONCLUSIONS: Our systematic review did not identify evidence of teratogenicity in babies exposed to everolimus as an immunosuppressant after transplantation. To better assess the risk of exposure to everolimus during pregnancy, all cases of new pregnancies occurring in transplant recipients receiving treatment with mammalian target of rapamycin inhibitor inhibitors should be reported.
摘要：
目的：关于怀孕期间使用依维莫司的安全性数据有限。在这项研究中,我们介绍了整个妊娠过程中使用依维莫司的母婴结局,并对妊娠期器官移植后使用依维莫司的报道进行了系统评价.
方法：接受肾脏移植的1型糖尿病患者接受他克莫司治疗，依维莫司,和泼尼松龙。两年后,她怀孕了.妊娠27周时,由于严重的先兆子痫和胎儿窘迫，进行了紧急剖宫产。在矫正年龄为4个月的婴儿中没有发现先天性畸形，母体肾功能保持稳定。
结论：我们的系统评价没有发现移植后暴露于依维莫司作为免疫抑制剂的婴儿的致畸性证据。为了更好地评估怀孕期间暴露于依维莫司的风险，所有接受哺乳动物雷帕霉素靶蛋白抑制剂治疗的移植受者发生新妊娠的病例均应报告.
方法：接受肾脏移植的1型糖尿病患者接受他克莫司治疗，依维莫司,和泼尼松龙。两年后,她怀孕了.妊娠27周时,由于严重的先兆子痫和胎儿窘迫，进行了紧急剖宫产。在矫正年龄为4个月的婴儿中没有发现先天性畸形，母体肾功能保持稳定。
结论：我们的系统评价没有发现移植后暴露于依维莫司作为免疫抑制剂的婴儿的致畸性证据。为了更好地评估怀孕期间暴露于依维莫司的风险，所有接受哺乳动物雷帕霉素靶蛋白抑制剂治疗的移植受者发生新妊娠的病例均应报告.
